Table 1 Population, microscopic and clinical characteristics of BRCA1-OC patients
From: Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer
No. of patients | Percent | |
|---|---|---|
Population, microscopic and clinical characteristics | 66 | 100 |
Age | ||
- ≤ 50 years | 34 | 51.5 |
- > 50 years | 32 | 48.5 |
Menopause | ||
- yes | 28 | 42.4 |
- no | 38 | 57.6 |
No. of births | ||
- 0 | 10 | 15.2 |
- 1 | 27 | 40.9 |
- ≥2 | 29 | 43.9 |
Family history | ||
- 1st degree relatives with ovarian cancer | 8 | 12.1 |
- 1st degree relatives with breast cancer | 17 | 25.8 |
Coexisting breast cancer | ||
- yes | 9 | 13.6 |
Type of BRCA1 gene mutation | ||
-C61G | 31 | 47 |
- 5382insC | 21 | 31.8 |
- 4153delAG | 6 | 9.1 |
- 189delAG | 4 | 6.1 |
- 3819del5 | 2 | 3 |
- IVS20 + 60ins12 | 1 | 1.5 |
- 4158A > G | 1 | 1.5 |
Grading of the tumor | ||
- G1 | 2 | 2.7 |
- G2 | 18 | 27.3 |
- G3 | 46 | 70 |
Histological type | ||
- serous | 27 | 40.9 |
- endometrial | 23 | 34.9 |
- undifferentiated | 8 | 12.1 |
- mucous | 4 | 6.1 |
- clear cell | 2 | 3 |
- mezonefroid | 2 | 3 |
Staging FIGO (2009) | ||
- I | 4 | 6.1 |
- II | 11 | 16.7 |
- III | 50 | 75.7 |
- IV | 1 | 1.5 |
Cytoreduction | ||
- primary | 44 | 66.7 |
- interval | 22 | 33.3 |
The overall extent of cytoreduction | ||
- optimal | 34 | 51.5 |
- suboptimal | 32 | 48.5 |
The average concentration of CA125 at the beginning of treatment | 1113 U/ml | |
The average concentration of CA125 at the end of treatment | 71 U/ml | |